focus -WSS

focus

author：entertainment 2025-08-26 10:52:16 - browse：6899

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Global cancer cases to surge 77% by 2050, WHO report says

hotspot

focus

WSS

The Biogen Aduhelm mess could happen again

Gene therapy for Afghan refugees’ infant will be fully covered

As billionaires fund anti

Adopting new red light myopia treatments may be short

Top private equity targets in 2023: cardiology, clinical trials, lasers

HHS's proposed rule does nothing to address the climate crisis

focus

focus

entertainment

What does generative AI mean for health care? We asked experts

Adopting new red light myopia treatments may be short

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

340B reform proposal comes out of Senate working group

Alkermes shareholders re

Brain MRIs reveal impact of 'toxic stress' on Black children

23andMe had bad news about my health. I wish a person had delivered it

A protest over insulin prices is seen as a fight for life

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

explore

The Biogen Aduhelm mess could happen again

Readout LOUD: Venture capital, Gilead, and more M&A

Devoted Health’s losses in Medicare Advantage persist

As billionaires fund anti

Readout Newsletter: Amgen, Regeneron, BGI Group and more

As health system earnings go up, health insurance stocks go down

hotspot

hotspot

focus

hotspot